Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

---

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., ...More

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Volume: 31
• Doi Number: 10.1016/j.annonc.2020.08.004
• Country: ELECTR NETWORK
• Open Archive Collection: AVESIS Open Access Collection
• Ankara University Affiliated: Yes